Selpercatinib - Save Up to 90% with Coupons, Discounts & Assistance Programs

Selpercatinib is available as a 40 mg and 80 mg oral capsule.

Selpercatinib is a RET inhibitor that is used to treat:

• Advanced or metastatic NSCLC with RET gene fusion in adults
• Advanced or metastatic thyroid cancers with RET mutations in adults and children age 12 years and older
• Advanced or metastatic tumors with RET mutations in adults, when other treatments haven’t worked or aren’t available

Selpercatinib is a protein in the body that signals cells to grow and divide. Your body makes RET proteins using instructions given by the RET gene. In certain cancers, changes (mutations) in the RET gene lead to abnormal RET proteins. These abnormal proteins cause cancer cells to grow out of control. Selpercatinib is a type of kinase inhibitor called a RET inhibitor. It blocks the RET protein, so the cancer can’t grow and spread as easily.

• The dose of Selpercatinib is based on your weight
• People weighing 110 lb or more: The typical dose is 160 mg by mouth twice a day, about 12 hours apart
• People weighing less than 110 lb: The typical dose is 120 mg by mouth twice a day, about 12 hours apart

Selpercatinib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Selpercatinib:

• Signs of stress to the liver or kidney on blood tests
• Abnormal electrolyte levels in the blood
• Lower blood cell counts
• Swelling
• Diarrhea
• Feeling very tired
• Dry mouth
• High blood pressure
• Stomach pain
• Constipation
• Rash
• Nausea
• Headache

Serious side effects are rare with Selpercatinib. Contact your healthcare provider immediately if you experience any of the following.

• Liver injury: pain in the right side of the stomach, yellowing of the eyes or skin, dark or brown urine
• Lung damage: cough, shortness of breath, fever
  High blood pressure: headache, dizziness, confusion, chest pain
• Abnormal heart rhythm: chest pain, shortness of breath, dizziness, fluttering or pounding heart beat
• Severe bleeding: sudden or painful headache, changes in vision, severe stomach pain, coughing or spitting up blood
• Tumor lysis syndrome: muscle cramps, dark or brown urine, fluttering or pounding heart beat
• Allergic reaction: fever, rash, muscle, bone, or joint pain

The following medications may interact with Selpercatinib:

• Acid-Reducing Agents: Avoid coadministration. If coadministrationncannot be avoided, take Selpercatinib with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid).
• • Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the Selpercatinib dose
• • Strong and Moderate CYP3A Inducers: Avoid coadministration. (CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling
• • Certain P-gp Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labelin.

Various FDA-approved generic manufacturers

Based on data from animal reproduction studies and its mechanism of action, Selpercatinib can cause fetal harm when
administered to a pregnant woman. If you can become pregnant, you should use effective contraception during treatment with Selpercatinib and for 1 week after the last dose. Males with female partners of reproductive potential to use effective contraception during treatment with Selpercatinib and for 1 week after the last dose.

• Retevmo